Reply letter to “Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial”
A recent study reported that the high-dose quadrivalent influenza vaccine provided superior immunogenicity and efficacy versus the standard-dose quadrivalent vaccine in the elderly. However, we need to view these results in terms of public health benefits as well. The Number Needed to Vaccinate (NNV...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-11-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2022.2085470 |
| _version_ | 1797673162461151232 |
|---|---|
| author | Sanjay Hadigal Laura Colombo Scott Haughie |
| author_facet | Sanjay Hadigal Laura Colombo Scott Haughie |
| author_sort | Sanjay Hadigal |
| collection | DOAJ |
| description | A recent study reported that the high-dose quadrivalent influenza vaccine provided superior immunogenicity and efficacy versus the standard-dose quadrivalent vaccine in the elderly. However, we need to view these results in terms of public health benefits as well. The Number Needed to Vaccinate (NNV) is an important tool to measure the benefit of a given vaccine. Further, NNV evaluates the benefits of a vaccine in preventing and controlling communicable diseases. Considering the target of vaccination and coverage of 75% not met in the elderly in Europe, it is important not to prioritize one vaccine over the other, but rather to increase the vaccine coverage with all the available vaccines. |
| first_indexed | 2024-03-11T21:40:45Z |
| format | Article |
| id | doaj.art-7fb7947901144b1284662f2cbd7108d2 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T21:40:45Z |
| publishDate | 2022-11-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-7fb7947901144b1284662f2cbd7108d22023-09-26T13:19:07ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2022-11-0118510.1080/21645515.2022.20854702085470Reply letter to “Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial”Sanjay Hadigal0Laura Colombo1Scott Haughie2ViatrisViatrisViatrisA recent study reported that the high-dose quadrivalent influenza vaccine provided superior immunogenicity and efficacy versus the standard-dose quadrivalent vaccine in the elderly. However, we need to view these results in terms of public health benefits as well. The Number Needed to Vaccinate (NNV) is an important tool to measure the benefit of a given vaccine. Further, NNV evaluates the benefits of a vaccine in preventing and controlling communicable diseases. Considering the target of vaccination and coverage of 75% not met in the elderly in Europe, it is important not to prioritize one vaccine over the other, but rather to increase the vaccine coverage with all the available vaccines.http://dx.doi.org/10.1080/21645515.2022.2085470number needed to vaccinatestandard-dose quadrivalent vaccinehigh-dose quadrivalent vaccinevaccine shortageat-risk group prioritizationvaccine coverageinfluenza vaccineflu |
| spellingShingle | Sanjay Hadigal Laura Colombo Scott Haughie Reply letter to “Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial” Human Vaccines & Immunotherapeutics number needed to vaccinate standard-dose quadrivalent vaccine high-dose quadrivalent vaccine vaccine shortage at-risk group prioritization vaccine coverage influenza vaccine flu |
| title | Reply letter to “Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial” |
| title_full | Reply letter to “Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial” |
| title_fullStr | Reply letter to “Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial” |
| title_full_unstemmed | Reply letter to “Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial” |
| title_short | Reply letter to “Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial” |
| title_sort | reply letter to immunogenicity and safety of a quadrivalent high dose inactivated influenza vaccine compared with a standard dose quadrivalent influenza vaccine in healthy people aged 60 years or older a randomized phase iii trial |
| topic | number needed to vaccinate standard-dose quadrivalent vaccine high-dose quadrivalent vaccine vaccine shortage at-risk group prioritization vaccine coverage influenza vaccine flu |
| url | http://dx.doi.org/10.1080/21645515.2022.2085470 |
| work_keys_str_mv | AT sanjayhadigal replylettertoimmunogenicityandsafetyofaquadrivalenthighdoseinactivatedinfluenzavaccinecomparedwithastandarddosequadrivalentinfluenzavaccineinhealthypeopleaged60yearsorolderarandomizedphaseiiitrial AT lauracolombo replylettertoimmunogenicityandsafetyofaquadrivalenthighdoseinactivatedinfluenzavaccinecomparedwithastandarddosequadrivalentinfluenzavaccineinhealthypeopleaged60yearsorolderarandomizedphaseiiitrial AT scotthaughie replylettertoimmunogenicityandsafetyofaquadrivalenthighdoseinactivatedinfluenzavaccinecomparedwithastandarddosequadrivalentinfluenzavaccineinhealthypeopleaged60yearsorolderarandomizedphaseiiitrial |